1. Home
  2. DMRA vs PRCT Comparison

DMRA vs PRCT Comparison

Compare DMRA & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$24.85

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation

HOLD

Current Price

$24.30

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRA
PRCT
Founded
2011
2009
Country
United States
United States
Employees
7
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
DMRA
PRCT
Price
$24.85
$24.30
Analyst Decision
Buy
Buy
Analyst Count
1
11
Target Price
$46.00
$35.44
AVG Volume (30 Days)
217.1K
1.2M
Earning Date
04-30-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1.71
EPS
N/A
N/A
Revenue
N/A
$308,054,000.00
Revenue This Year
N/A
$31.34
Revenue Next Year
N/A
$24.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
37.22
52 Week Low
$16.50
$19.35
52 Week High
$28.76
$64.89

Technical Indicators

Market Signals
Indicator
DMRA
PRCT
Relative Strength Index (RSI) 46.18 45.32
Support Level $23.65 $22.81
Resistance Level $28.00 $26.55
Average True Range (ATR) 2.13 1.14
MACD -0.14 0.10
Stochastic Oscillator 28.16 42.19

Price Performance

Historical Comparison
DMRA
PRCT

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Share on Social Networks: